

Paradigm Biopharmaceuticals Ltd

11:25 15 Nov 2018

Paradigm Biopharmaceuticals boosts financial position with \$2.32 million R&D tax rebate

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has strengthened its capital position after receiving a \$2.32 million Research & Development (R&D) Tax Incentive Refund for the 2017/2018 financial year.

The company's capital position now stands at \$10.5 million, boosted by the R&D refund as well as completion of tranche II of the October \$9 million capital raising.

This provides Paradigm with the funds to prepare regulatory filings with the US FDA and the Australian TGA following phase 2b read-out of results.

READ: Paradigm Biopharmaceuticals enters agreement to treat US-based sportspeople

CEO Paul Rennie said: "Receipt of this R&D rebate is well timed with the upcoming release of the primary endpoint for the 110-patient phase 2b OA randomised double-blind, placebo-controlled, multi-centre clinical trial.

"Data QC, analysis and preparation of documents for regulatory submissions in 2019 are underway for the phase 2b OA clinical trial.

"The clinical trial remains on its original timeline and within the financial budget with the readout of results in mid to late December 2018 to be a major value inflexion point for the company."




Paradigm's strong financial position will assist in funding preparations for US Compassionate Use/Expanded Access and US FDA IND submissions.

Price: 2.83

Market Cap: \$636.03 m

1 Year Share Price Graph



Share Information

Code: PAR

Listing: ASX

52 week High Low
4.5 1.08

Sector: Pharma & Biotech

Website: www.paradigmbiopharma.com

Company Synopsis:

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com.au

Rennie added: "Our strong financial position is significant as it allows us to continue to accelerate our OA programs and regulatory filings.

"We also intend to bring forward other value-add initiatives that we are working on and we look forward to updating the market on these activities in due course."

READ: Paradigm Biopharmaceuticals secures \$9 million to accelerate phase III

The Australian Government's R&D Tax Incentive encourages companies to engage in R&D benefiting Australia, by providing a refundable tax offset of up to 43.5% for eligible R&D activities.

Focused on repurposing PPS

Paradigm is focused on repurposing pentosan polysulfate sodium (PPS), an FDA approved drug.

Injectable PPS is not currently registered in Australia but is registered in four of the seven major global pharmaceutical markets.

In European markets, injectable PPS is registered as an antithrombotic agent.

Injectable PPS for human use is not available for sale in Australia and is only available by inclusion into a Paradigm sponsored clinical trial or via a treating physician applying for its use in patients via the TGA's SAS - Category B.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).